Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819569 · ClinicalTrials.gov registry record · NA
GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses
A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 265
- Enrollment target
NCT03819569 is a NA study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 265 participants.
The verdict
NCT03819569, a NA study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 265 participants
- Enrollment target
Study Summary
Purpose: The purpose of this study is to evaluate the role of renal mass biopsy on decision-making for patients presenting with clinical T1 kidney tumors. This study also incorporates integrated biomarker study to compare the genomic data obtained through biopsy tissue to genomic information from surgical data.
Interventions
- PROCEDURE Small Renal Mass Biopsy
- OTHER No Small Renal Mass Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2024-04-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03819569
The ClinicalTrials.gov registry entry for NCT03819569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Small Renal Mass Biopsy is the first listed.
NCT03819569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03819569 about?
NCT03819569 is a clinical study titled "GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses". Purpose: The purpose of this study is to evaluate the role of renal mass biopsy on decision-making for patients presenting with clinical T1 kidney tumors. This study also incorporates integrated biomarker study to compare the genomic data obtained through biopsy tissue to genomic information from su...
What is the current status of trial NCT03819569?
This trial is currently completed. It is a NA study. The enrollment target is 265 participants. The study started on 2018-10-30. Estimated completion is 2024-04-18.
What interventions are being tested in trial NCT03819569?
The interventions under investigation include: Small Renal Mass Biopsy (PROCEDURE), No Small Renal Mass Biopsy (OTHER).
Who is sponsoring clinical trial NCT03819569?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.